Previous Article | Next Article 
Journal of Virology, January 1999, p. 576-584, Vol. 73, No. 1
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A Packaging Cell Line for Lentivirus
Vectors
Tal
Kafri,
Henriette
van Praag,
Ling
Ouyang,
Fred H.
Gage, and
Inder M.
Verma*
Laboratory of Genetics, The Salk Institute,
La Jolla, California 92037
Received 24 August 1998/Accepted 8 October 1998
 |
ABSTRACT |
Lentivirus vectors can transduce dividing and nondividing cells.
Using three-plasmid transient transfections, high-titer
(>109 IU/ml) recombinant lentivirus vectors pseudotyped
with vesicular stomatitis virus G (VSV-G) protein can be generated
(T. Kafri et al., Nat. Genet. 17:314-317, 1997; H. Miyoshi et al.,
Proc. Natl. Acad. Sci. USA 94:10319-10323, 1997; L. Naldini et al., Science 272:263-267, 1996). The recombinant lentiviruses can
efficiently infect brain, liver, muscle, and retinal tissue in vivo.
Furthermore, the transduced tissues demonstrated long-term expression
of reporter genes in immunocompetent rodents. We now report the
generation of a tetracycline-inducible VSV-G pseudotyped lentivirus
packaging cell line which can generate virus particles at titers
greater than 106 IU/ml for at least 3 to 4 days. The vector
produced by the inducible cell line can be concentrated to titers of
109 IU/ml and can efficiently transduce nondividing cells
in vitro and in vivo. The availability of a lentivirus packaging cell
line will significantly facilitate the production of high-titer
lentivirus vectors for gene therapy and study of human immunodeficiency
virus biology.
 |
INTRODUCTION |
Retrovirus vectors have been used
extensively for gene therapy (23). However, currently
available recombinant retroviral vectors are not suitable for in vivo
gene delivery because they can transduce dividing cells only. The
advent of lentivirus vectors has overcome this obstacle and can
efficiently transduce a variety of tissues in vivo, including brain,
liver, muscle, retina, and hematopoietic cells. Sustained expression of
the transgene in the transduced tissues of immunocompetent mice or rats
further boosts their utility as a desirable vector for gene therapy.
Human immunodeficiency virus (HIV)-based vectors have been generated by
transient transfection of (i) the packaging construct plasmid encoding
Gag-Pol, Tat, Rev, Nef, Vpr, Vpu, and Vif proteins; (ii) a plasmid
encoding vesicular stomatitis virus G (VSV-G) protein; and (iii) the
vector containing the HIV long terminal repeats (LTRs), packaging
signal, Rev response element, and foreign promoter driving the
transgene (10, 13-15). Recombinant viruses with titers of
3 × 106 IU/ml were generated which could be
concentrated by centrifugation to titers of 1 × 109
to 3 × 109 IU/ml (10, 12, 13). To
facilitate vector production for in vivo experiments in larger animals
we need to develop a stable VSV-G pseudotyped lentivirus vector
packaging cell line. An earlier report on the development of a
tetracycline-inducible VSV-G pseudotyped murine leukemia virus vector
packaging cell line encouraged us to adopt a similar approach
(16). Lentivirus vector packaging cells have
previously been described but the vector titers were quite low
(1, 3, 6, 18, 19, 25). Additionally, some of the
viral accessory proteins in these cell lines were either missing or
nonfunctional (25). In some of these cell lines, the gene
encoding the envelope protein and the genes encoding the packaging
proteins were transcribed from the same expression cassette, thereby
increasing the probability of generation of helper viruses.
Furthermore, none of the earlier cell lines expressed the VSV-G
envelope protein that allows vector concentration and expands the range
of target tissues. A major hurdle in the construction of a packaging
cell line generating recombinant lentiviruses was that VSV-G and some
HIV proteins, including protease and Vpr, have been reported to be
cytotoxic (11, 17, 20). Here we describe the generation of
an inducible lentivirus vector packaging cell line that was constructed
in 293 cells and that constitutively expresses a
tetracycline-regulated transactivator (tTA) (8, 9).
All HIV type 1 (HIV-1) genes (excluding the HIV-1 envelope gp
120) are transcribed in the cell line from a single expression cassette, which is regulated by tetracycline (8). In
addition, the cell line expresses the VSV-G envelope protein and
the green fluorescent protein (GFP) from a bidirectionl
tetracycline-regulated promoter. This gives the advantage not only of
pseudotyping the lentivirus vectors with the VSV-G envelope but
also of monitoring the induction process. A rapid and high level of
gene induction can be obtained by the addition of sodium butyrate.
Following transduction by lentivirus vectors, the novel packaging cell
line can generate vector particles at titers greater than
106 IU/ml for at least 3 to 4 days. The vectors produced by
the inducible cell line can be concentrated and can transduce
growth-arrested cells in culture and in terminally differentiated
neurons in immunocompetent rats.
 |
MATERIALS AND METHODS |
Plasmid construction.
pSKVG was constructed by cloning the
EcoRI VSV-G (Indiana serotype) from pMDG (15)
into the EcoRI site of Bluescript SK+. The GFP
coding fragment was excised from pEGFP-N1 by
SacI-NotI digestion and ligated to the
SacI-NotI fragment of Bluescript SK+
to create pSKGFP. The PstI fragment containing the GFP
coding region from pSKGFP was ligated to the PstI site in
pBI (Clontech 6152-1) to create pBIGF. The
NheI-EcoRV fragment containing the VSV-G coding
region from pSKVG was ligated to the XbaI-PvuII
sites in pBIGF to create pBIGFVS. The BamHI-BglII
fragment containing a minimal cytomegalovirus (CMV) immediate-early
gene promoter linked to seven tandem copies of the tetR-binding site
replaced the CMV promoter (BglII-BamHI fragment)
in pcDNAneo to create phCMVn. The plasmid pPTK was constructed by
ligation of the BglI-SacII fragment bearing the
genes encoding all the HIV-1 proteins from p
R8.2 (14) to
the BglI (partial)-SacII fragment from phCMVn. The XhoI fragment containing the neomycin resistance gene
was deleted from ptTet-Off (Clontech K1620-A) to create ptTA
n, from which a fusion protein containing the carboxy terminus of the tetracycline repressor and the herpes simplex virus VP16
transactivation domain is expressed under the control of the CMV
promoter. The pCLBFP was constructed by ligation of the
BamHI-EcoRI fragment containing the blue
fluorescent protein (BFP) gene from pEBFP (Clontech 6068-1) into the
BamHI-EcoRI fragment of pCL. The
HindIII-NotI fragment containing the BFP
coding region was inserted into the HindIII-NotI fragment of pcDNA3.1/hygro
(Invitrogen V870-20) to create pcDNABFP.
Vector production.
All the cell lines in this study were
maintained in Dulbecco's modified Eagle's medium containing
tetracycline-free 10% fetal calf serum (Clontech 8630-1). To generate
the stable cell line SODk0 that expresses the fusion protein
tetracycline repressor-VP16 transactivation domain, human 293 embryonic
kidney cells were cotransfected with 20 µg of ptTA
n and 1 µg of
pSR
BSR that expresses the blastocydine resistance gene by the
calcium phosphate precipitation method (5). Individual cell
colonies were selected with 20 µg of blastocydine/ml. The lentivirus
vector stable packaging cell line SODk1 was generated by transfection
of SODk0 cells with 10 µg of pPTK and 10 µg of pBIGFVS. The
transfected cells were selected for neomycin resistance (400 µg/ml)
in the presence of 0.7 µg of doxycycline/ml. Individual colonies were
screened for HIV-1 p24 and GFP production and cell fusion in the
presence or absence of doxycycline as follows. Cells from a confluent
10-cm plate were split by a ratio of 1:4 into PolyLysine precoated
plates. Induced cells were cultured in the absence of doxycycline. Cell media were changed daily. Control cells were cultured in the presence of 0.7 µg of doxycycline/ml. On day 4 postinduction, the levels of
HIV-1 p24 in conditioned media were measured by enzyme-linked immunosorbent assay (ELISA) (DuPont). Cell fusion was used as a marker
for VSV-G production, and GFP production was determined by fluorescence
microscopy. The colony that was found to be negative for p24 and GFP
production in the presence of doxycycline and yet showed the highest
levels of p24 production (>800 ng/ml) with more than 85% green cells
upon induction was chosen as the packaging cell line for the
lentivirus vector. The lentivirus vector producer cell line
SODk1CGFI was generated by transducing SODk1 cells with HRcmvGFP lentivirus vector using a multiplicity of infection
(MOI) of 2.
SODk1CGFI cells were split from a confluent 10-cm plate into a
precoated PolyLysine plate at a ratio of 1:4 in the absence of
doxycycline. Twenty-four hours after the split, the cells were washed
twice with phosphate-buffered saline (PBS) and refed with doxycycline-free media that contained 5 mM sodium butyrate. The media
were replenished daily. Induced SODk1CGFI-conditioned media were
filtered through a 0.45-µm-pore-size filter and assayed daily for
vector titers and p24 concentration by serial dilutions on 293 cells
and by p24 ELISA, respectively. To further concentrate the vector,
conditioned media were collected 3 days after addition of sodium
butyrate filtered as described above and ultracentrifuged at
50,000 × g for 2 h. The pellet was resuspended
and incubated for 2 h at 37°C in Tris-buffered saline (TBS)
containing 10 mM MgCl2, four dNTPs (0.1 mM each), 3 mM spermine, and
0.3 mM spermidine. After a second ultracentrifugation at
50,000 × g for 2 h, the vector was resuspended in
TBS with 2 µg of Polybrene/ml. The concentrated vector was
assayed for p24 concentration and titrated on 293 cells as described above.
Protein analysis.
Induced (3 days after adding sodium
butyrate) and uninduced (cultured in the presence of doxycycline) cells
were lysed, and proteins were denatured by boiling for 10 min in a
buffer containing 68 mM Tris (pH 6.8), 50 mM NaCl, 0.5 mM EDTA, 20 µg
of aprotinin/ml, 50 µg of phenylmethylsulfonyl fluoride/ml, 1.5%
sodium dodecyl sulfate (SDS), 5% glycerol, and 5%
-mercaptoethanol. Twenty micrograms of the denatured protein was
separated on a 12.5% polyacrylamide gel containing SDS and blotted
onto an Immobilon-P membrane (Millipore). After blocking with 5%
nonfat milk in PBS-0.2% Tween 20 for 15 min, the membranes were
incubated with mouse monoclonal anti-VSV-G (Sigma V-5507) or with
rabbit HIV-1 Vpr (National Institute of Allergy and Infectious
Diseases, AIDS Research and Reference Reagent Program, reagent 3252)
and then with goat anti-mouse immunoglobulin horseradish peroxidase
(Pierce) or donkey anti-rabbit horseradish peroxidase (Amersham),
respectively. The protein bands were detected with an ECL kit (Amersham).
Transduction of nondividing cells.
Serial dilution of
induced SODkCGFVGI-conditioned media was used to transduce either HeLa
cells arrested by culturing in the presence of 15 µg of
aphidicolin/ml for 12 h or human embryo fibroblasts arrested by
culturing for 48 h in 0.1% fetal calf serum. Titers were scored
48 h posttransduction by dividing the number of GFP-positive foci
by the dilution factor.
Assays for replication-competent virus.
We used three
independent methods to assay for replication-competent virus.
(i) tat transfer assay.
This assay is based on a
reporter HeLa P4.2 cell line which expresses CD4 and contains an
integrated lacZ reporter gene driven by the HIV LTR. Since
the HIV LTR is not active in naive HeLa cells, the expression of the
lacZ gene in P4.2 cells can serve as a sensitive indicator
for the presence of HIV tat (4). The sensitivity
of the assay was of 20 tat-transducing units per ml of test
medium. The use of the P4.2 cell line as an indicator of HIV-1 helper
activity in lentivirus vector stocks was described extensively in the
past (15). In our assay, 105 P4.2 cells were
transduced with 106 IU of the vector. The transduced cells
were serially passaged for 3 weeks (about five passages), after which
they were scored for HIV-1 tat activity by X-Gal
(5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside) staining. Using this method, no transduction of tat was detected.
(ii) HIV gag transfer assay.
This method is
based on measuring p24gag in conditioned media
obtained from vector-transduced cells. The use of this method
to assay for HIV-1 helper activity in lentivirus vector stocks and its
sensitivity was previously described (15). In our assay, 105 p4.2 cells were transduced by vector particles at an
MOI of 10. Following five passages in culture, the concentration of
p24gag in conditioned media obtained from these
cells was determined by ELISA (p24 ELISA kit; NEN Life Science
Products). The detection limit of this method is
1 pg/ml, which is
about 1 to 2 IU/ml. By this method, vector preparation is considered
helper negative when p24 concentrations are below detection levels.
(iii) Marker rescue assay.
A total of 105 p4.2
cells transduced with HR'CMVGFP lentivirus vector
(p4.2G.) were plated on a 10-cm-diameter plate and transduced with
106 IU of the tester vector stock. The transduced cells
were cultured for 3 weeks, after which conditioned medium was harvested
and filtered through a 0.45-µm-pore-size filter. A total of
105 293T cells were transduced in a 10-cm plate with 10 ml
of the medium in the presence of 4 µg of Polybrene/ml. Seventy-two
hours posttransduction, the cells were scored for GFP expression.
Vector stock was considered helper free when no green cells were detected.
FACS analysis.
Trypsinized cells were resuspended in 5 ml of
culture medium and washed in PBS minus Ca2+ and
Mg2+. The cells were fixed in 3 ml of 5% paraformaldehyde,
washed twice in PBS, and diluted in PBS to a concentration of
106 cells/ml. Fluorescence-activated cell sorter (FACS)
analysis for cellular GFP and BFP was performed by FACScan analysis
(Becton Dickinson) with the CellQuest program (version 3.0.1f; Becton Dickinson).
RNA analysis.
Total cellular RNA was isolated by using a
Qiagen RNeasy kit. RNA (8 mg) was electrophoresed on a 1.2%
agarose-formaldehyde gel, transferred to Hybond-N+
(Amersham) membrane, and hybridized at 68°C to a
32P-labelled DNA probe. The membrane was washed twice
for 15 min in buffer containing 0.1% SDS-2× SSC (1× SSC is 0.15 M
NaCl plus 0.015 M sodium citrate) at 68°C and once in buffer
containing 0.1% SDS-0.1× SSC at 68°C for 15 min. The washed
membrane was exposed to Kodak X-Omat Blue XB-1 film.
Transduction of brain of immunocompetent rat.
Adult female
Fisher 344 rats (n = 6) were anesthetized (80 mg of
ketamine, 0.75 mg of acepromazine, and 4 mg of xylazine per ml/per kg
of body weight), and 2 µl of the viral-vector concentrated stock
(1 × 109 IU/ml) was injected into the left striatum
(anterior-posterior, +1; medial lateral, 3.5; dorsal-ventral, 4) with a
10-µl Hamilton syringe. After 4 weeks, the rats were deeply
anesthetized and perfused intracardially with 100 ml of saline followed
by 200 ml of 4% paraformaldehyde. Brains were postfixed for 24 h
and stored in 30% phosphate-buffered sucrose at 4°C until
sectioning. Brains were frozen and sectioned on a sliding microtome
into 40-µm slices. Sections were washed and blocked in TBS with 3%
donkey serum and 0.3% Triton X-100 (TBS plus). Primary antibodies
raised in two different species were pooled in TBS-plus and incubated for 48 h at 4°C. The antibody for Neu-N (mouse monoclonal
antibody [a generous gift of R. J. Mullin]; 1:20) was combined
with antibody for GFAP (glialfibrillary acidic protein) (guinea pig
polyclonal antibody [Advanced Immunochemicals]; 1:500). Corresponding
secondary antibodies (donkey anti-mouse Texas red and donkey
anti-guinea pig Cy5; 1:250) were pooled, and sections were incubated
for 4 h at room temperature following washing in TBS plus. Every
12th section was mounted and coverslipped with DABCO-PVA. Sections were
analyzed by confocal scanning laser microscopy (Bio-Rad). To determine
the nature of transduced cells, double-labelled sections were scanned
with a confocal laser microscope, and a representative sample of 100 transduced cells was examined for colocalization of GFP with either
NeuN or GFAP.
 |
RESULTS |
SODk0: a tTA cell line.
The extensive characterization of the
tetracycline-inducible system encouraged us to use this regulatory
control in the development of the lentivirus vector packaging cell
line. As a first step, we generated a 293 (human embryonic kidney) cell
line that constitutively expresses the tTA. The tTA is a fusion product
of the amino terminal-DNA binding domain of the tet
repressor and the carboxy-terminal activation domain of VP-16 from
herpes simplex virus (8). In the absence of tetracycline,
tTA binds to the tet-responsive elements (TRE) in the
tet operator (tet0) and efficiently activates
transcription from downstream minimal promoters. The association
between tTA and the TRE is prevented by tetracycline; therefore, in the
presence of low concentrations of tetracycline or its derivative
deoxycycline, transcription from TRE is turned off. We cotransfected
293 cells with a plasmid, ptTA
n, that expresses tTA from the early
promoter of CMV and with plasmid pSR
BSR expressing the blastocidine
resistance gene from the SR
promoter (21). Stably
transfected clones were selected by culturing in the presence of
blastocidine, and 20 cell clones whose growth rates did not differ
significantly from that of the parental 293 cells were screened for tTA
expression. Each clone was cotransfected with plasmid pBIGF that
expresses GFP from a tetracycline-regulated promoter and plasmid
pcDNABFP expressing BFP from a CMV promoter. The transfected cells were cultured either in the presence or the absence of doxycycline, a potent
derivative of tetracycline (9). By fluorescence microscopy and FACS analysis we could evaluate the relative expression of GFP (as
a reporter for tTA activity) and the expression of BFP (as a standard
for transfection efficiency and transcription activity). The FACS
analysis of SODk0 cells transfected with pBIGF and pcDNABFP in the
presence of doxycycline shows little GFP, whereas in the absence of
deoxycycline, intense GFP staining can be identified. Based on the
relative induction of GFP and the efficiency of transfection (Fig. 1), we chose SODk0 as a
parental cell line for development of inducible lentiviral vector
packaging cell line.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 1.
Screening for tTA-expressing 293 cells. Human embryonic
kidney 293 cell clones that stably expressed the tTA gene were
transiently cotransfected with the pBIGF plasmid that produced the GFP
under the control of the tetracycline-regulated promoter and the
pcDNABFP plasmid that expressed the BFP under the control of the CMV
promoter. Activation of the tetracycline-regulated promoter by the tTA
in the presence and the absence of doxycycline (DOX) was evaluated by
GFP expression and was determined by FACS analysis (x axis).
BFP expression from the CMV promoter served as a standard for
transfection efficiency and transcription activity and was determined
by FACS analysis (y axis). Nontransfected human embryonic
kidney 293 cells that expressed the tTA gene served as a negative
control for either GFP or BFP expression.
|
|
SODk1 packaging cell line.
To generate an inducible VSV-G
pseudotyped lentivirus packaging cell line, we molecularly cloned the
VSV-G gene and the entire HIV packaging cassette into
tetracycline-inducible vectors. The VSV-G gene was cloned into
pBIGF to generate pBIGFVG from which the GFP and the VSV-G are
transcribed under the regulation of a bidirectional
tetracycline-inducible promoter (Fig. 2).
The HIV-1 packaging cassette was cloned into phCMVn to generate
pPTK, from which all HIV-1 genes (except the HIV-1 envelope
gp120) are expressed under the control of a tetracycline-regulated
promoter (Fig. 2). Before establishing a producer cell line, we wanted to evaluate the potential of inducible packaging systems to produce virus particles. Therefore, we transiently cotransfected
SODk0 cells with the inducible packaging plasmid pPTK,
the inducible envelope plasmid pBIGFVS, or the previously described
pMDG plasmid that expresses the VSV-G envelope under the regulation
of the CMV promoter and the vector plasmid pCLCG (12). To
standardize vector production, we also generated vector particles by
transiently transfecting 293T cells with the vector plasmid pCLCG, pMDG
(VSV-G envelope), and the
R8.2 (packaging) plasmids that were
previously described (14). Based on p24 (viral
gag) levels in the conditioned media of transfected cells
and the actual vector titers (Table 1),
we conclude that vector production by the tetracycline-regulated packaging and envelope constructs is similar if not more efficient than
the transient three-plasmid transfection method previously employed
(10, 12-15).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Inducible envelope and packaging constructs. pBIGFVG is
an inducible plasmid that expresses the VSV-G envelope and the GFP
genes under the control of a bidirectional tetracycline-inducible
promoter. This promoter contains two human CMV minimal promoters (ph1
and ph2) separated by the TRE. Arrows indicate transcription
directions. The simian virus 40 (SV40) and -globin polyadenylation
signals are indicated. The pPTK plasmid contains an HIV-1 genomic
fragment that encodes all HIV-1 genes excluding the HIV-1 envelope
( R.8.2) under the regulation of an inducible promoter. This promoter
contains the TRE and the human CMV minimal promoter (pHCMV). Also
indicated are the bovine growth hormone polyadenylation signal (BGHpA),
the SV40 promoter and origin (SV40ori), the neomycin resistance gene
(Neo), the SV40 polyadenylation signal (SV40pA), the
ColE1 origin (ColE1 ori), and the f1 origin (f1ori).
|
|
Encouraged by these results, we embarked on the establishment of a
stable packaging cell line. The pPTK packaging construct
that also
expresses the neomycin resistance gene (Fig.
2) and
the pBIGFVG
envelope construct were cotransfected into the SODk0
cell line.
Thirty-five stably transfected cell clones were isolated
and screened
for inducible regulation of the VSV-G-GFP and the
HIV packaging
cassettes. Twenty cell clones in which at least
90% of the cells
turned green 48 h after the withdrawal of doxycycline
were
selected. The second stage of the screening was aimed at
the
isolation of the clone in which the highest expression levels
of
the HIV-1 packaging proteins were obtained following induction.
The
cells were cultured in the presence or absence of
doxycycline,
and HIV
gag protein production was
determined by p24
gag ELISA. The SODk1
clone was found to be most promising since the
p24
gag concentration in the media was below
detection level in the presence
of doxycycline and higher than 800 ng/ml without
it.
Induction by sodium butyrate.
Surprisingly, the percentage of
SODk1 cells that turned green upon doxycycline withdrawal gradually
declined and within 1 month of the isolation of the SODk1 clone, less
than 10% of the cells could be induced to express GFP. In parallel, we
observed a prolongation in the time required to reach maximal levels of p24gag. Interestingly, this phenomenon was
common to all 20 cell clones. The fact that the SODk1 cells were
resistant to blastocidine and neomycin indicated that the tTA and the
packaging plasmids were still integrated in their genome. We attributed
the changes in the kinetics and magnitude of SODk1 cells induction to
chromatin remodeling. To test this assumption, SODk1 cells were
transduced with the pLBFPL vector in which the expression of the BFP is
controlled by the HIV-1 LTR. Since the activation of the HIV LTR in 293 cells is tat dependent, we could monitor the induction of
the pPTK packaging plasmid by monitoring BFP expression. Expression of
pPTK will provide the tat protein, which in turn will
activate HIV LTR to transcribe and express BFP. We hypothesized that a
potent inhibitor of deacetylation, such as sodium butyrate (22,
24), could revert some of the repressive effects of chromatin on
tetracycline-regulated promoters. To test our hypothesis, SODk1Blue
cells were cultured in the absence of tetracycline and 48 h later,
5 mM of sodium butyrate was added to half of the samples. By FACS
analysis, we evaluated the induction of the pBIGFVG envelope and the
pPTK packaging constructs by the expression of the GFP and the BFP,
respectively. Figure 3 demonstrates that
sodium butyrate has a dramatic effect on the magnitude of induction in
SODk1 cells. The time course analysis of SODk1 cells in the presence of
sodium butyrate shows that the activation of the pPTK packaging plasmid
and the pBIGFVG envelope is relatively synchronized and reaches maximal
levels 3 to 4 days after doxycycline withdrawal (Fig.
4). To further evaluate the efficiency of
doxycycline regulation of gene expression, we measured the amount of
both the Vpr (one of the products of pPTK) and the VSV-G (encoded by
pBIGFVG) proteins by Western blot analysis. Constitutive expression of
these proteins is not compatible with long-term cell culturing because
both proteins are cytostatic or cytotoxic (7, 17, 20).
Results shown in Fig. 5A indicate that,
although the expression of both proteins is nearly undetectable in the
presence of doxycycline (lanes 1 and 3), it is dramatically increased
upon doxycycline withdrawal and butyrate treatment (lanes 2 and 4). We
therefore conclude that the SODk1 cell line allows regulated production
of both HIV viral proteins required for packaging and VSV-G-encoded
envelope protein. We next tested if the increased amount of VSV-G
protein was in fact due to enhanced transcription of VSV-G gene in the
presence of sodium butyrate. Figure 5B (lane 3) shows that, in the
absence of deoxycycline, the addition of sodium butyrate leads to a
greater-than-10-fold increase in VSV-G mRNA. Thus, the addition of
sodium butyrate directly affects transcription, which is reflected in
the increased virus titers (see below).

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 3.
Induction by sodium butyrate. SODk1Blue cells were
induced by doxycycline (DOX) withdrawal in the presence or absence of
sodium butyrate. Expression of the BFP and GFP was determined by FACS
analysis (y and x axis, respectively) and
reflected the activation of the inducible HIV-1 packaging and the VSV-G
envelope cassettes, respectively. Noninduced SODk1Blue cells served as
a negative control.
|
|

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of SODk1Blue cells. SODk1Blue cells were
induced by doxycycline withdrawal in the presence of sodium butyrate.
Activation of the VSV-G envelope and the HIV-1 packaging cassettes was
reflected by the expression levels of the GFP and the BFP genes,
respectively, and was determined at days 0, 2, 3, and 4 postinduction
by FACS analysis.
|
|

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 5.
(A) Western blot analysis of Vpr and VSV-G protein
induction. SODk1 cells were induced by doxycycline (DOX) withdrawal and
sodium butyrate (BUT) treatment. Three days postinduction, production
of the HIV-1 Vpr (lanes 3 and 4) and the VSV-G envelope protein (lanes
1 and 2) in noninduced (lanes 1 and 3) and induced (lanes 2 and 4)
cells was determined by Western blot analysis. (B) Northern analysis.
Total RNA was extracted from either noninduced SODk1 cells that were
cultured in the presence of doxycycline (+DOX) or from SODk1 cells that
were induced by doxycycline withdrawal in the presence ( DOX + BUT) or the absence ( DOX) of 5 mM sodium butyrate (upper part of
figure). RNA samples were ethidium bromide stained and electrophoresed
in a 1.2% agarose gel (lower part of figure). The efficiency of RNA
transfer to positively charged membrane was determined by UV
fluorescence. The position of the 1.6-kb VSV-G mRNA is indicated with
an arrow.
|
|
Lentivirus vector producer cell line.
To generate a producer
cell line, SODk1 cells were transduced with CLCG lentivirus vector at
an MOI of 2. The CLCG vector in the three-plasmid transfections
(12) expresses GFP under the control of the CMV
promoter; therefore, we could use fluorescence microscopy to determine
that between 80 and 90% of SODK1 cells were transduced. Since
uninduced SODK1 cells were not producing VSV-G protein, there was
presumably no interference to transduction by the CLCG vector
containing VSV-G protein. To induce vector production, the cells were
cultured in the absence of doxycycline for 24 h followed by the
addition of 5 mM of sodium butyrate to half of the samples.
Culture medium was replenished every 24 h, and vector
production was determined by p24gag ELISA and by
serial dilutions on 293T cells. Table 2
shows that 2 × 105 IU/ml of vector can be generated
in 24 h following the addition of sodium butyrate by the stable
lentivirus vector producer cell lines. By day 4, nearly 3 × 106 IU/ml of recombinant viruses can be obtained; however,
vector production at later time points was significantly reduced due to
lower cell viability. The producer cells fuse to form syncytia (7). Furthermore, there was a correlation between the actual vector titers that were determined by serial dilutions on 293T cells
and the expected titer based on p24gag
concentration. In the absence of sodium butyrate, the increase in
p24gag concentration was significantly slower.
Although the maximal p24gag concentration was
not affected by the absence of sodium butyrate, the actual vector titer
as determined by serial dilutions on 293T cells was more than 100-fold
lower than the titer obtained in the presence of butyrate. Since less
than 90% of the SODk1CG1 cells were transduced with the GFP-expressing
lentivirus vector, we could increase the titers by reinfecting the
cells with the same lentivirus vector (data not shown).
We next examined the lentivirus vector preparations from the SODk1CG1
cell line for the presence of helper virus. As in the
past, we have
relied on three independent methods: (i) the marker
rescue assay; (ii)
the
tat transfer assay on vector-transduced
P4.2 cells; and
(iii) the p24
gag ELISA on vector-transduced P4.2
cells. No replication-competent
helper virus could be detected by these
methods (
15).
Properties of viral vectors obtained from the packaging cell line
SODk1CG1.
To test the transduction of nondividing cells with
lentivirus vectors produced by the SODk1CG1 packaging cell line, human embryonic fibroblasts (HEF) and HeLa cells were growth arrested at the
G1/S boundary of the cell cycle by culturing in low-serum media (0.1% fetal calf serum) or by aphidicolin treatment,
respectively. Table 3 shows that
lentivirus vector that was generated by the SODk1CG1 packaging
cell line was as efficient at transducing
G1-arrested cells as proliferating cells.
To investigate if the vector produced by SODk1CG1 packaging cell line
can transduce nondividing cells in vivo, we concentrated
the vector by
ultracentrifugation to titers of 10
9 IU/ml. Two microliters
of concentrated recombinant vector was
injected into the corpus
striatum of adult rat brain. Four weeks
postinjection, the brains were
sectioned and analyzed for GFP
expression by confocal microscopy. Using
immunofluorescence staining
with antibodies for NeuN and GFAP, we could
determine whether
the transduced cells were neurons or astrocytes. The
results shown
in Fig.
6 demonstrate that
the vector produced by the SODk1CG1
cell line can efficiently transduce
terminally differentiated
nondividing neurons. About 60% of the
transduced cells were neurons,
32% of the transduced cells were
astrocytes, and the remaining
8% showed neither marker. Preferential
transduction of neurons
over glial cells by lentivirus vectors was
previously reported
(
15), and the mechanism responsible for
that has not yet been
characterized.

View larger version (86K):
[in this window]
[in a new window]
|
FIG. 6.
Transduction of brain of immunocompetent rat.
Representative coronal section (40 µm thick) of a rat brain with
unilateral striatal injection of 2 µl of vector expressing GFP 4 weeks after injection. Low magnification (bar = 1 mm) and high
magnification (inset) (bar = 100 µm) are shown. Double labelling
for NeuN (red) and GFAP (blue) was used.
|
|
 |
DISCUSSION |
Lentivirus vectors have the ability to deliver and to maintain
long-term expression of transgenes in a broad range of tissues in vivo.
To date, these vectors have been generated by transient three-plasmid
transfections (10, 12-15). Although this method allows the
generation of high-titer vectors, it limits the amount of vector
particles that can be produced. It was important, therefore, to
develop a stable cell line that can reproducibly generate high-titer lentivirus vectors in amounts that allow lentivirus-based gene therapy
on large animal models.
The fact that HIV protease, VSV-G, and HIV vpr
genes have been reported to be cytotoxic or cytostatic when
constitutively expressed mandated the use of an inducible system.
Alternatively, we could substitute the VSV-G envelope with a nontoxic
envelope gene (e.g., amphotropic env) and delete the
accessory proteins from the HIV packaging cassette. This could allow us
to screen for cell clones resistant to the HIV protease and yet
constitutively produce vector particles. Our decision to establish an
inducible cell line was based on two major considerations. First, we
did not want to lose the major advantages offered by the VSV-G
envelope, namely, the broad range of target tissues and the ability for vector concentration by ultracentrifugation (2). Second, we did not want to limit the use of the lentivirus vector produced by the
packaging cell line to tissues that may need complementation for the
lack of HIV accessory proteins. Additionally we assumed that the
cytotoxic effect of the HIV protease could eventually induce negative
selection for cells that express this protein even if the parental cell
clone was resistant to the protease. We chose to develop a regulated
packaging cell line based on the well-defined and characterized
tetracycline-inducible system (8, 9).
In the process of establishing the inducible lentivirus vector
packaging cell line, we observed a gradual decline in the reactivation of tetracycline-regulated promoters. The fact that addition of 5 mM
sodium butyrate to the culture media overrode the silencing process
indicated that this phenomenon was in part the result of changes in
chromatin remodeling in the tetracycline-regulated promoters.
Interestingly, in the absence of sodium butyrate,
p24gag production reached its maximal level
within 4 to 6 days of doxycycline withdrawal. This result was in
accordance with data presented in an earlier report showing that
expression of HIV packaging proteins from a tetracycline-regulated
promoter reached its maximal levels 6 to 7 days after
tetracycline withdrawal (25). Although maximal production of
the HIV packaging proteins in the absence of sodium butyrate was not
lower than the maximal level obtained in the presence of butyrate,
vector titers were almost 100-fold lower in the absence of butyrate.
This observation can be explained by inefficient induction of the
bidirectional tetracycline-regulated promoter from which the GFP and
the VSV-G envelope protein are expressed. Clearly, sodium butyrate
enhances transcription (Fig. 5B). However, we cannot rule out the
possibility that part of the increase in vector titers stems from the
effect of butyrate on HIV LTR or other endogenous genes.
Interestingly, secondary transduction of SODk1CG1 cells with the GFP
lentivirus vector results in a significant increase in vector titers
(9a), which correlated with proportional increase of
p24gag levels in conditioned media. It is
interesting, therefore, to investigate additional rounds of vector
transduction and see if p24gag levels and vector
titers increase. The uncloned populations of SODk1CG1
packaging cell line that have been generated in this study
produce high-titer VSV-G pseudotyped lentivirus vectors (up to 3 × 106 IU/ml). It is therefore
reasonable to assume that even higher titers can be obtained once
individual clones can be screened for the highest producer.
In spite of the high-titer vector production, we did not detect helper
virus in any of our vector preparations. There are several elements in
our cell line that reduce the probability of generating replication
competent virus. (i) The HIV packaging unit, the envelope, and the
vector RNA are transcribed from separate expression units. (ii) The
VSV-G envelope does not share any sequence homology with the vector or
the packaging transcripts. (iii) The transcription of the vector, the
envelope, and the packaging unit is limited to the time of induction.
(iv) The VSV-G envelope is cytotoxic and therefore reduces the
probability of being constitutively expressed. We believe these are
important safety features. Further removal of additional viral genes
(e.g., vpr, vpu, nef, vif,
etc.) will add safety features to the lentivirus vector.
In summary, we report here the establishment of a
tetracycline-regulated lentivirus vector packaging cell line that
reproducibly generates helper-free, high-titer VSV-G pseudotyped
vectors. These vectors have a broad spectrum of target tissues and can
be concentrated by ultracentrifugation to very high titers (higher than
109 IU/ml). Vectors produced by the new packaging cell
lines efficiently transduced G1/S arrested cells in vitro
and terminally differentiated neurons in brain of immunocompetent rat.
The new packaging cell line allows large-scale production of lentivirus
vectors and therefore will facilitate human gene therapy efforts.
 |
ACKNOWLEDGMENTS |
We are grateful to D. Chambers for help with FACS analysis and to
J. Simon, L. Grabowski, M. Gage, and B. Coyne for help in preparation
of the manuscript; we also thank members of the Verma and Gage
laboratories for their interest in this work.
This work was supported by grants from the National Institutes of
Health, National Institute for Aging, the American Paralysis Association, and the Hollfelder Foundation. T.K. is supported by a
fellowship from the Cystic Fibrosis Foundation. We gratefully acknowledge the support of the Frances Berger Foundation and the March
of Dimes. I.M.V. is an American Cancer Society Professor of Molecular Biology.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory of
Genetics, The Salk Institute, 10010 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (619) 453-4100. Fax: (619) 558-7454. E-mail:
verma{at}salk.edu.
 |
REFERENCES |
| 1.
|
Buchschacher, G. L., Jr., and A. T. Panganiban.
1992.
Human immunodeficiency virus vectors for inducible expression of foreign genes.
J. Virol.
66:2731-2739[Abstract/Free Full Text].
|
| 2.
|
Burns, J. C.,
T. Friedmann,
W. Driever,
M. Burrascano, and J. K. Yee.
1993.
Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells.
Proc. Natl. Acad. Sci. USA
90:8033-8037[Abstract/Free Full Text].
|
| 3.
|
Carroll, R.,
J.-T. Lin,
E. J. Dacquel,
J. D. Mosca,
D. S. Burke, and D. C. St. Louis.
1994.
A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines.
J. Virol.
68:6047-6051[Abstract/Free Full Text].
|
| 4.
|
Charneau, P.,
G. Mirambeau,
P. Roux,
S. Paulous,
H. Buc, and F. Clavel.
1994.
HIV-1 reverse transcription. A termination step at the center of the genome.
J. Mol. Biol.
241:651-662[Medline].
|
| 5.
|
Chen, C. A., and H. Okayama.
1988.
Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA.
BioTechniques
6:632-638[Medline].
|
| 6.
|
Corbeau, P.,
G. Kraus, and F. Wong-Staal.
1996.
Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line.
Proc. Natl. Acad. Sci. USA
93:14070-14075[Abstract/Free Full Text].
|
| 7.
|
Eidelman, O.,
R. Schlegel,
T. S. Tralka, and R. Blumenthal.
1984.
pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstituted into phospholipid vesicles.
J. Biol. Chem.
259:4622-4628[Abstract/Free Full Text].
|
| 8.
|
Gossen, M., and H. Bujard.
1992.
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Proc. Natl. Acad. Sci. USA
89:5547-5551[Abstract/Free Full Text].
|
| 9.
|
Gossen, M.,
S. Freundlieb,
G. Bender,
G. Muller,
W. Hillen, and H. Bujard.
1995.
Transcriptional activation by tetracyclines in mammalian cells.
Science
268:1766-1769[Abstract/Free Full Text].
|
| 9a.
| Kafri, T. Unpublished results.
|
| 10.
|
Kafri, T.,
U. Blomer,
D. A. Peterson,
F. H. Gage, and I. M. Verma.
1997.
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.
Nat. Genet.
17:314-317[Medline].
|
| 11.
|
Kaplan, A. H., and R. Swanstrom.
1991.
The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity.
Biomed. Biochim. Acta
50:647-653[Medline].
|
| 12.
|
Miyoshi, H.,
U. Blömer,
M. Takahashi,
F. H. Gage, and I. M. Verma.
1998.
Development of a self-inactivating lentivirus vector.
J. Virol.
72:8150-8157[Abstract/Free Full Text].
|
| 13.
|
Miyoshi, H.,
M. Takahashi,
F. H. Gage, and I. M. Verma.
1997.
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.
Proc. Natl. Acad. Sci. USA
94:10319-10323[Abstract/Free Full Text].
|
| 14.
|
Naldini, L.,
U. Blomer,
F. H. Gage,
D. Trono, and I. M. Verma.
1996.
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.
Proc. Natl. Acad. Sci. USA
93:11382-11388[Abstract/Free Full Text].
|
| 15.
|
Naldini, L.,
U. Blomer,
P. Gallay,
D. Ory,
R. Mulligan,
F. H. Gage,
I. M. Verma, and D. Trono.
1996.
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
Science
272:263-267[Abstract].
|
| 16.
|
Ory, D. S.,
B. A. Neugeboren, and R. C. Mulligan.
1996.
A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.
Proc. Natl. Acad. Sci. USA
93:11400-11406[Abstract/Free Full Text].
|
| 17.
|
Planelles, V.,
F. Bachelerie,
J. B. M. Jowett,
A. Haislip,
Y. Xie,
P. Banooni,
T. Masuda, and I. S. Y. Chen.
1995.
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr.
J. Virol.
69:5883-5889[Abstract].
|
| 18.
|
Richardson, J. H.,
L. A. Child, and A. M. L. Lever.
1993.
Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5' leader region.
J. Virol.
67:3997-4005[Abstract/Free Full Text].
|
| 19.
|
Rizvi, T. A., and A. T. Panganiban.
1993.
Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles.
J. Virol.
67:2681-2688[Abstract/Free Full Text].
|
| 20.
|
Rogel, M. E.,
L. I. Wu, and M. Emerman.
1995.
The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection.
J. Virol.
69:882-888[Abstract].
|
| 21.
|
Takebe, Y.,
M. Seiki,
J. Fujisawa,
P. Hoy,
K. Yokota,
K. Arai,
M. Yoshida, and N. Arai.
1988.
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
Mol. Cell. Biol.
8:466-472[Abstract/Free Full Text].
|
| 22.
|
Turner, B. M.
1991.
Histone acetylation and control of gene expression.
J. Cell Sci.
99:13-20[Free Full Text].
|
| 23.
|
Verma, I. M., and N. Somia.
1997.
Gene therapy promises, problems and prospects.
Nature
389:239-242[Medline].
|
| 24.
|
Wade, P. A.,
D. Pruss, and A. P. Wolffe.
1997.
Histone acetylation: chromatin in action.
Trends Biochem. Sci.
22:128-132[Medline].
|
| 25.
|
Yu, H.,
A. B. Rabson,
M. Kaul,
Y. Ron, and J. P. Dougherty.
1996.
Inducible human immunodeficiency virus type 1 packaging cell lines.
J. Virol.
70:4530-4537[Abstract].
|
Journal of Virology, January 1999, p. 576-584, Vol. 73, No. 1
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Throm, R. E., Ouma, A. A., Zhou, S., Chandrasekaran, A., Lockey, T., Greene, M., De Ravin, S. S., Moayeri, M., Malech, H. L., Sorrentino, B. P., Gray, J. T.
(2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood
113: 5104-5110
[Abstract]
[Full Text]
-
Jones, G. S., Yu, F., Zeynalzadegan, A., Hesselgesser, J., Chen, X., Chen, J., Jin, H., Kim, C. U., Wright, M., Geleziunas, R., Tsiang, M.
(2009). Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase. Antimicrob. Agents Chemother.
53: 1194-1203
[Abstract]
[Full Text]
-
Davis, J., Westfall, M. V., Townsend, D., Blankinship, M., Herron, T. J., Guerrero-Serna, G., Wang, W., Devaney, E., Metzger, J. M.
(2008). Designing Heart Performance by Gene Transfer. Physiol. Rev.
88: 1567-1651
[Abstract]
[Full Text]
-
Yu, J. H., Schaffer, D. V.
(2006). Selection of novel vesicular stomatitis virus glycoprotein variants from a Peptide insertion library for enhanced purification of retroviral and lentiviral vectors.. J. Virol.
80: 3285-3292
[Abstract]
[Full Text]
-
Logan, A. C., Haas, D. L., Kafri, T., Kohn, D. B.
(2004). Integrated Self-Inactivating Lentiviral Vectors Produce Full-Length Genomic Transcripts Competent for Encapsidation and Integration. J. Virol.
78: 8421-8436
[Abstract]
[Full Text]
-
Mata, M., Glorioso, J. C., Fink, D. J.
(2003). Gene Transfer to the Nervous System: Prospects for Novel Treatments Directed at Diseases of the Aging Nervous System. Journals of Gerontology Series A: Biological Sciences and Medical Sciences
58: M1111-1118
[Abstract]
[Full Text]
-
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F. III, Hynes, N. E.
(2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA
100: 8933-8938
[Abstract]
[Full Text]
-
Kubo, S., Mitani, K.
(2003). A New Hybrid System Capable of Efficient Lentiviral Vector Production and Stable Gene Transfer Mediated by a Single Helper-Dependent Adenoviral Vector. J. Virol.
77: 2964-2971
[Abstract]
[Full Text]
-
Kobayashi, M., Iida, A., Ueda, Y., Hasegawa, M.
(2003). Pseudotyped Lentivirus Vectors Derived from Simian Immunodeficiency Virus SIVagm with Envelope Glycoproteins from Paramyxovirus. J. Virol.
77: 2607-2614
[Abstract]
[Full Text]
-
Vacek, M. M., Ma, H., Gemignani, F., Lacerra, G., Kafri, T., Kole, R.
(2003). High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA. Blood
101: 104-111
[Abstract]
[Full Text]
-
Mitta, B., Rimann, M., Ehrengruber, M. U., Ehrbar, M., Djonov, V., Kelm, J., Fussenegger, M.
(2002). Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. Nucleic Acids Res
30: e113-e113
[Abstract]
[Full Text]
-
Ortego, J., Escors, D., Laude, H., Enjuanes, L.
(2002). Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome. J. Virol.
76: 11518-11529
[Abstract]
[Full Text]
-
Gatlin, J., Melkus, M. W., Padgett, A., Kelly, P. F., Garcia, J. V.
(2001). Engraftment of NOD/SCID Mice with Human CD34+ Cells Transduced by Concentrated Oncoretroviral Vector Particles Pseudotyped with the Feline Endogenous Retrovirus (RD114) Envelope Protein. J. Virol.
75: 9995-9999
[Abstract]
[Full Text]
-
Williams, D. A., Nienhuis, A. W., Hawley, R. G., Smith, F. O.
(2000). Gene Therapy 2000. ASH Education Book
2000: 376-393
[Abstract]
[Full Text]
-
Takahashi, M., Miyoshi, H., Verma, I. M., Gage, F. H.
(1999). Rescue from Photoreceptor Degeneration in the rd Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer. J. Virol.
73: 7812-7816
[Abstract]
[Full Text]
-
Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M., Torbett, B. E.
(1999). Transduction of Human CD34+ Cells That Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors. Science
283: 682-686
[Abstract]
[Full Text]